HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hiroshi Fukui Selected Research

CDAA (Randox)

3/2015Reduction of endotoxin attenuates liver fibrosis through suppression of hepatic stellate cell activation and remission of intestinal permeability in a rat non-alcoholic steatohepatitis model.
11/2013Direct renin inhibitor, aliskiren, attenuates the progression of non-alcoholic steatohepatitis in the rat model.
7/2013Dual blockade of angiotensin-II and aldosterone suppresses the progression of a non-diabetic rat model of steatohepatitis.
5/2009Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat.
11/2008Innate immune reactivity of the liver in rats fed a choline-deficient L-amino-acid-defined diet.
11/2007Crosstalk between high-molecular-weight adiponectin and T-cadherin during liver fibrosis development in rats.
7/2003Extracellular matrix remodeling may predominate over hepatocyte injury in hepatocellular carcinoma development.
7/2002Inhibition of renin-angiotensin system attenuates liver enzyme-altered preneoplastic lesions and fibrosis development in rats.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Hiroshi Fukui Research Topics

Disease

40Liver Cirrhosis (Hepatic Cirrhosis)
01/2021 - 07/2002
30Neoplasms (Cancer)
12/2017 - 03/2002
28Hepatocellular Carcinoma (Hepatoma)
11/2019 - 04/2002
18Fibrosis (Cirrhosis)
11/2019 - 07/2002
10Liver Diseases (Liver Disease)
06/2021 - 01/2002
9Inflammation (Inflammations)
01/2021 - 06/2009
9Fatty Liver
11/2019 - 01/2006
9Alcoholic Fatty Liver
03/2015 - 06/2007
8Infections
06/2021 - 06/2004
8Ascites
01/2021 - 01/2002
7Alcoholic Liver Diseases (Alcoholic Liver Disease)
06/2021 - 08/2002
6Endotoxemia
01/2021 - 08/2002
6Body Weight (Weight, Body)
01/2021 - 08/2003
6Chronic Hepatitis C
12/2014 - 02/2005
6Insulin Resistance
08/2013 - 04/2006
6Acute Liver Failure (Fulminant Hepatic Failure)
03/2011 - 07/2006
6Carcinogenesis
10/2006 - 07/2002
5Hepatic Encephalopathy
01/2021 - 07/2003
5Hemorrhage
09/2017 - 11/2005
5Hepatitis
09/2017 - 09/2005
5Non-alcoholic Fatty Liver Disease
10/2015 - 10/2006
5Alcoholic Hepatitis
02/2010 - 08/2004
4Dysbiosis
06/2021 - 09/2017
4Disease Progression
01/2018 - 11/2006
4Thrombosis (Thrombus)
08/2017 - 01/2003
3Multiple Organ Failure (MODS)
02/2018 - 11/2005
3Portal Hypertension
04/2016 - 01/2015
3Ulcer
01/2009 - 01/2006
3Chronic Pancreatitis
06/2008 - 11/2004
2Cognitive Dysfunction
06/2021 - 11/2019
2Chronic Hepatitis (Chronic Active Hepatitis)
11/2018 - 01/2006
2Hepatitis B
11/2018 - 08/2017
2Cholangitis
02/2018 - 01/2002
2Liver Failure
01/2018 - 10/2011
2Pleural Effusion (Pleural Effusions)
08/2017 - 10/2002
2Hepatitis C
08/2017 - 07/2016

Drug/Important Bio-Agent (IBA)

21Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA
01/2012 - 03/2002
18Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2011 - 03/2002
16EndotoxinsIBA
06/2021 - 08/2002
13CytokinesIBA
06/2021 - 08/2002
11Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
06/2021 - 08/2002
11Amino AcidsFDA Link
01/2021 - 07/2002
10InterferonsIBA
12/2014 - 02/2005
10Choline (Choline Chloride)IBA
10/2014 - 07/2002
9Angiogenesis Inducing Agents (Angiogenesis Factor)IBA
08/2010 - 03/2002
8CDAA (Randox)IBA
03/2015 - 07/2002
8Proteins (Proteins, Gene)FDA Link
12/2014 - 10/2002
8Pharmaceutical PreparationsIBA
12/2014 - 07/2003
8PerindoprilFDA LinkGeneric
11/2006 - 03/2002
7Anti-Bacterial Agents (Antibiotics)IBA
01/2021 - 10/2010
7DiureticsIBA
01/2021 - 05/2014
7Angiotensin IIIBA
07/2013 - 09/2003
7Messenger RNA (mRNA)IBA
08/2008 - 04/2002
6EnzymesIBA
01/2021 - 07/2002
6Branched-Chain Amino AcidsIBA
07/2016 - 01/2009
6Glutathione Transferase (Glutathione S-Transferase)IBA
11/2013 - 07/2003
5Toll-Like Receptor 4IBA
06/2021 - 08/2008
5Ethanol (Ethyl Alcohol)IBA
09/2007 - 08/2002
4Interleukin-8 (Interleukin 8)IBA
06/2021 - 07/2005
4TolvaptanFDA Link
01/2021 - 07/2016
4von Willebrand FactorIBA
11/2018 - 01/2007
4Biomarkers (Surrogate Marker)IBA
11/2018 - 07/2003
4AntigensIBA
09/2017 - 06/2008
4AldosteroneIBA
08/2017 - 05/2010
4Vasopressin Receptors (Arginine Vasopressin Receptor)IBA
08/2017 - 11/2015
4SteroidsIBA
07/2016 - 10/2008
4Ribavirin (Virazole)FDA LinkGeneric
07/2016 - 01/2006
4CollagenIBA
03/2015 - 07/2002
4Vitamin KFDA Link
05/2011 - 01/2007
4Transforming Growth Factor beta (TGF-beta)IBA
05/2009 - 05/2006
4Imatinib Mesylate (Gleevec)FDA Link
04/2009 - 05/2005
3InterleukinsIBA
06/2021 - 02/2010
3Metalloproteases (Metalloproteinases)IBA
09/2017 - 06/2008
3ReninIBA
08/2017 - 01/2005
3Sorafenib (BAY 43-9006)FDA Link
12/2014 - 05/2012
3Chelating AgentsIBA
06/2011 - 09/2003
3Therapeutic UsesIBA
04/2011 - 01/2003
3Immunoglobulin G (IgG)IBA
01/2011 - 01/2006
3Vitamin K 2 (Vitamin K2)IBA
08/2009 - 01/2006
3Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA
01/2009 - 12/2006
3radixinIBA
07/2008 - 11/2003
3Bromhexine (Bisolvon)IBA
06/2008 - 11/2004
3Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA
06/2007 - 03/2002
3Alanine Transaminase (SGPT)IBA
11/2006 - 01/2002
3Hydroxyproline (4 Hydroxyproline)IBA
05/2005 - 07/2002
3Tissue Inhibitor of Metalloproteinase-1IBA
09/2003 - 10/2002
2DisaccharidesIBA
01/2021 - 07/2016
2LipopolysaccharidesIBA
11/2019 - 05/2010
2SolutionsIBA
01/2018 - 02/2007
2ThrombospondinsIBA
09/2017 - 06/2008
2AlbuminsIBA
07/2016 - 03/2012

Therapy/Procedure

32Therapeutics
01/2018 - 03/2002
6Chemoprevention
10/2014 - 11/2004
5Liver Transplantation
06/2021 - 01/2010
5Drug Therapy (Chemotherapy)
05/2016 - 01/2006
3Sclerotherapy
07/2016 - 11/2005
2Surgical Portasystemic Shunt (Portosystemic Shunt)
01/2018 - 02/2017
2Catheters
01/2018 - 09/2007
2Peritoneovenous Shunt
01/2018 - 02/2017
2Aftercare (After-Treatment)
08/2017 - 05/2011